论文部分内容阅读
目的探讨阿托伐他汀对不稳定性心绞痛(UA)患者血浆高敏C-反应蛋白(hs-CRP)和冠状动脉粥样硬化的影响。方法测定30例不稳定性心绞痛患者在常规治疗基础上口服阿托伐他汀(商品名立普妥)20mg,治疗12个月前后血浆hs-CRP及经16排螺旋CT冠状动脉钙化检查测定的冠状动脉斑块的变化,并与常规治疗30例作为对照组。结果30例不稳定性心绞痛患者经阿托伐他汀治疗12个月后血浆hs-CRP显著下降(P<0.01),冠状动脉钙化灶亦明显缩小(P<0.01),相关分析提示,冠状动脉钙化灶的缩小幅度与LDL胆固醇水平相关(r=0.54,P<0.01)。不稳定性心绞痛患者用阿托伐他汀治疗12个月后,心血管事件发生率显著下降(P<0.01)。结论阿托伐他汀通过抗炎等机制对防治不稳定性心绞痛冠状动脉粥样硬化及稳定斑块起着重要的作用。
Objective To investigate the effect of atorvastatin on plasma high-sensitivity C-reactive protein (hs-CRP) and coronary atherosclerosis in patients with unstable angina (UA). Methods 30 patients with unstable angina pectoris were treated with oral atorvastatin (Lipitor, 20mg) on the basis of routine treatment. Plasma hs-CRP and coronary artery calcification were measured by 16-slice spiral CT before and after treatment for 12 months Arterial plaque changes, and with conventional treatment of 30 cases as a control group. Results Thirty months after treatment with atorvastatin in patients with unstable angina, plasma hs-CRP decreased significantly (P <0.01) and coronary artery calcification decreased significantly (P <0.01). Correlation analysis showed that coronary artery calcification Focal lesion was related to LDL cholesterol level (r = 0.54, P <0.01). After 12 months of treatment with atorvastatin in patients with unstable angina, the incidence of cardiovascular events decreased significantly (P <0.01). Conclusion Atorvastatin plays an important role in the prevention and treatment of coronary atherosclerosis and stable plaque in patients with unstable angina pectoris through anti-inflammatory and other mechanisms.